Table 1: Reviewed articles of CHMCF pregnancies.

Author

Year

# Cases

Number

Diagnosed at Gestional Age (GA)

Amniocentesis

Termination at Gestional Age

Live neonate

BHCG (IU/L)

Pre-eclampsia

Theca luteine cysts

Fundal height (weeks Gestational Age (GA))

Persistent Gestational Trophoblastic Neoplasia

Chemotherapy

Miller

1993

4

a

16

16

0

645456

X

cisplatinum, etoposide, mtx, actinomycine D

b

22

46,XX

38

1

383000 at GA22, then falling

0

c

18

18

0

1620000

X

0

d

17

46,XY

19

0

GA 17: 302000, GA 19: 3200000

x

mtx and actinomycine D

Steller

1994

8

a

15

0

2460000

X

X

30

X

EMA

b

21

0

256000

21

X

MTX

c

13

0

500000

X

20

X

ACTd and EMA

d

24

0

1048

X

30

X

MTX

e

13

0

955000

17

X

MTX, EMA, VBP

f

19

0

1365080

X

30

g

23

0

60000

X

34

h

31

1

?

31

Anderson

1996

1

a

36

36

1

248000

36

x

MTX

Bristow

1996

26

7

Hurteau

1997

1

a

9

10

0

600000

x

MTX, actinomycine D

Shahabi

1997

2

a

17

46, XX

38

1

falling

b

17

yes

17

0

GA 8: 276047, rising GA 16: 880000, GA 17: 1224680

x

MTX

Chen

1997

1

a

18

46, XY

38

1

X

MTX, actinomycine D

Fishman

1998

7

a

18

b

15

c

34

1

X

MTX

d

15

e

26

1

X

MTX

f

18

X

MTX

g

23

X

MTX

Kauffman

1999

1

a

16

46,XY

28

1

GA 16: 177980, falling

X

MTX

Abbi

1999

1

a

36

37

1

GA 36: 95000

Jauniaux

1999

3

a

46,XX

14

b

46,XX

37

1

falling

c

2x46,XY

17

rising

hypertension

Matsui

2000

72

16

19,4%

30,6%

Bruchim

2000

2

a

41

1

b

46,XY

26

1

35 MoM

X

MTX

Benirschke

2001

1

a

28

46, XX

40

1

Kwon

2002

1

a

19

19

0

321000 at GA 19

X

MTX-CF

Sebire

2002

77

20

19%

Moini

2003

1

19

36

1

47000 at GA 19?

Aggarwal

2004

1

20

20

150000

Steigrad

2004

2

a

13

46,XX

32

1

254000 at GA 13, falling

b

12

46,XX and 46, XY

34

2

157000 at GA 22, falling

X

MTX

Marcorelles

2005

4

a

13

46,XY

32

1

10000 at GA 32

b

18

46,XX

38

1

c

14

46,XX

15

0

409970

X

too high

d

15

46,XX

21

0

920000

X

X

too high

Lambert

2005

2

a

19

23

1

4,03 MoM at GA 16

b

28

1

6,39 MoM at GA 16

Vaisbuch

2005

2

a

15

16

928390

x

x

b

21

46, XX

26

1

200000

x

Wee

2005

174

43%

27%

23%

35%

Hancock

2006

9

5

3

MTX

Ogura

2006

2

a

15

17

1850 ng/ml (GA 16)

x

20

x

MTX-CF

b

20

21

351 ng/ml (GA 20)

26

Niemann

2007

8

a

21

46,XX

23

182480

b

18

diploid

18

c

18

46,XX

27

1

1142260

d

20

46,XX

20

X

MTX

e

9

46,XX

11

254880

f

10

46,XY

14

180000

g

6

46,XY

11

492500

X

MTX

h

10

46,XY and 46,XX

14

1216888

True

2007

1

23

26

1

1000000

Yamada

2008

1

10

15

774840

X

X

Ema/co

Piura

2008

1

12

46,XX

28

1

697930, falling

Massardier

2009

14

3

3

7

Dolapcioglu

2009

2

a

13

46,XY

29

1

198000, falling

b

15

46,XY

18

0

512000

x

x

23

Albayrak

2010

1

17

33

1

69000

Lee

2010

6

a

13

20

0

500000

X

b

14

46, XX

38

1

245000, falling

X

MTX

c

10

46, XX

500000

X

d

13

14

665105

X

MTX-CF

e

12

18

371000

X

f

13

13

1307693

X

MTX-CF

Kihara

2012

17

5

6

8

Dalmia

2013

1

10

46, XX

37

1

Ferraz

2013

1

12

12

1402565

X

Vimercati

2013

2

a

19

27

1

231000

b

16

46, XX

26

1

353273

Huang

2013

1

8

46, XY

15

Okumura

2014

1

15

46,XY

32

1

200000, falling

x

x

Kutuk

2014

7

a

23

34

1

100048

x

b

20

23

0

15774

c

18

21

0

141720

d

12

14

0

310270

e

12

14

0

125220

x

No chemotherapy, hysterectomy

f

17

21

0

310351

g

11

11

0

351660

Peng

2014

1

20

46,XY

37

1

310277

x

MTX, switch to EMA/CO

Büke

2014

1

17

46,XX

32

1

77509, falling

Rohilla

2015

2

a

15

46, XY

20

0

x

b

19

19

0

Sheik

2015

1

13

17

0

1386570

x